Maximum androgen blockade
Maximum androgen blockade (MAB), also known as combined androgen blockade (CAB), is a medical treatment strategy for advanced prostate cancer. It involves the use of a combination of medications to block the effects of androgens, the male sex hormones, in the body. This is achieved by inhibiting the production of androgens and blocking their effects on the prostate cancer cells.
Mechanism of action[edit]
The primary mechanism of action of maximum androgen blockade is the inhibition of androgen receptors. These receptors are proteins found in both normal and cancerous prostate cells that bind to androgens and stimulate cell growth. By blocking these receptors, MAB prevents androgens from promoting the growth of prostate cancer cells.
In addition to receptor blockade, MAB also involves the use of medications that inhibit the production of androgens. This is achieved by suppressing the function of the testes, which are the primary source of androgens in the body, and the adrenal glands, which produce a smaller amount of androgens.
Treatment regimen[edit]
The typical treatment regimen for maximum androgen blockade involves the use of a luteinizing hormone-releasing hormone (LHRH) agonist or antagonist, which inhibits the production of androgens by the testes, in combination with an antiandrogen medication, which blocks the effects of androgens on the prostate cancer cells.
The LHRH agonists used in MAB include medications such as leuprolide and goserelin, while the LHRH antagonists include degarelix. The antiandrogen medications used in MAB include bicalutamide, flutamide, and nilutamide.
Efficacy and side effects[edit]
Several clinical trials have shown that maximum androgen blockade can improve survival in men with advanced prostate cancer. However, the treatment is associated with a number of side effects, including hot flashes, sexual dysfunction, and an increased risk of cardiovascular disease.
See also[edit]
| Prostate cancer | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
This prostate cancer related article is a stub.
|
| Diseases of the endocrine system (E00–E35, 240–259) | ||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Sponsored Health Resource

W8MD Weight Loss, Sleep & MedSpa
Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.
GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.
- Medical weight loss NYC
- Affordable GLP-1 injections NYC
- Budget GLP-1 weight loss shots Philadelphia
- New Jersey medical weight loss
- NYC medical weight loss blog
- Philadelphia weight loss blog
- Sleep medicine and sleep apnea services
- W8MD MedSpa and wellness
Book a W8MD appointment · View GLP-1 specials
Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
